TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands

OBJECTIVE: Neovascular age-related macular degeneration (nAMD) causes damage to the macula and severe vision loss. Bevacizumab is the most cost-effective nAMD treatment. The TANDEM trial was designed to determine whether, in patients with nAMD, low-dose bevacizumab is non-inferior to the standard do...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Alexander, Haydock, Rebecca, Childs, Margaret, Duley, Lelia M, Empeslidis, Theo, Dhar-Munshi, Sushma, Montgomery, Alan A, Ogollah, Reuben, Ozolins, Mara, Tesha, Paul, Mitchell, Eleanor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Global Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725082/
https://www.ncbi.nlm.nih.gov/pubmed/33344775
http://dx.doi.org/10.1136/bmjophth-2020-000588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725082/
https://www.ncbi.nlm.nih.gov/pubmed/33344775
http://dx.doi.org/10.1136/bmjophth-2020-000588

Ejemplares similares